Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07616128 · ClinicalTrials.gov registry record · Phase 2
Study of EVO756 in Adults With Migraine
A Phase 2 study, sponsored by Evommune.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 330
- Enrollment target
NCT07616128 is a Phase 2 study that is actively recruiting participants, run by Evommune. The registered enrollment target is 330 participants.
The verdict
NCT07616128, a Phase 2 study, is actively recruiting participants, sponsored by Evommune.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 330 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
Interventions
- DRUG Placebo
- DRUG EVO756, Dose 1
- DRUG EVO756, Dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07616128
The ClinicalTrials.gov registry entry for NCT07616128 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Evommune, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07616128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07616128 about?
NCT07616128 is a clinical study titled "Study of EVO756 in Adults With Migraine". This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
What is the current status of trial NCT07616128?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 330 participants. The study started on 2026-06. Estimated completion is 2027-11.
What interventions are being tested in trial NCT07616128?
The interventions under investigation include: Placebo (DRUG), EVO756, Dose 1 (DRUG), EVO756, Dose 2 (DRUG).
Who is sponsoring clinical trial NCT07616128?
This trial is sponsored by Evommune, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.